# Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

> **NCT00724984** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 55 (actual)

## Conditions studied

- Lymphoma
- Hodgkin Disease
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** PCI-24781

## Key facts

- **NCT ID:** NCT00724984
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-11
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2014-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724984, "Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00724984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*